{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:38:02Z","timestamp":1783406282623,"version":"3.54.6"},"reference-count":43,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2018,3,6]]},"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare baseline characteristics between patients with psoriatic arthritis (PsA) who achieved and did not achieve minimal disease activity (MDA) with biologic therapy in the US-based Corrona Psoriatic Arthritis\/Spondyloarthritis Registry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with PsA aged \u226518 years enrolled between March 2013 and March 2016 who were receiving biologics at enrolment (baseline), not in MDA and had \u22652\u2009follow-up visits were included. Patients were classified as those who remained on their index biologic and achieved MDA at the second follow-up visit (MDA achievers (MDA-A)) and those who did not (MDA non-achievers (MDA-NA)). Demographics, clinical characteristics, patient-reported outcomes and medication history were compared between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 148 patients with PsA who met the inclusion criteria, 34 (23.0%) and 114 (77.0%) were classified as MDA-A and MDA-NA, respectively. At baseline, most patients (96.6%) were receiving tumour necrosis factor inhibitors, and both groups were similar in age, sex, race, medication history, enthesitis and dactylitis counts, disease duration and comorbidities. Compared with MDA-A, MDA-NA had significantly worse mean tender joint count (7.2 vs 3.4), patient-reported pain (51.2 vs 35.7), patient-reported fatigue (54.1 vs 42.4), physical function (Health Assessment Questionnaire, 1.0 vs 0.6), Bath Ankylosing Disease Activity Index (5.0 vs 3.4) and Bath Ankylosing Spondylitis Functional Index (4.0 vs 2.0) scores (all p&lt;0.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Approximately one in four patients achieved MDA with their index biologic at the time of the second follow-up visit. Both groups were similar in several baseline demographic and clinical features; however, patients who did not achieve MDA generally had worse tender joint counts and patient-reported outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2017-000638","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T07:10:09Z","timestamp":1524640209000},"page":"e000638","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry"],"prefix":"10.1136","volume":"4","author":[{"given":"Philip J","family":"Mease","sequence":"first","affiliation":[{"name":"Rheumatology Clinical Research Division, Swedish Medical Center and University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Karki","sequence":"additional","affiliation":[{"name":"Corrona, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[{"name":"Corrona, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[{"name":"University of California San Diego, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T","family":"Ritchlin","sequence":"additional","affiliation":[{"name":"Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doquyen Hoa","family":"Huynh","sequence":"additional","affiliation":[{"name":"Scripps Health, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline B","family":"Palmer","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Corrona, Waltham, Massachusetts, USA"},{"name":"Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,4,25]]},"reference":[{"key":"2025090312012948000_4.1.e000638.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"2025090312012948000_4.1.e000638.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.003"},{"key":"2025090312012948000_4.1.e000638.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu237"},{"key":"2025090312012948000_4.1.e000638.4","first-page":"680","article-title":"The burden of psoriatic arthritis: a literature review from a global health systems perspective","volume":"35","author":"Lee","year":"2010","journal-title":"P T"},{"key":"2025090312012948000_4.1.e000638.5","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315582354"},{"key":"2025090312012948000_4.1.e000638.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"2025090312012948000_4.1.e000638.7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312012948000_4.1.e000638.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"2025090312012948000_4.1.e000638.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"2025090312012948000_4.1.e000638.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"2025090312012948000_4.1.e000638.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"2025090312012948000_4.1.e000638.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"2025090312012948000_4.1.e000638.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"2025090312012948000_4.1.e000638.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"2025090312012948000_4.1.e000638.15","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"2025090312012948000_4.1.e000638.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2025090312012948000_4.1.e000638.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"2025090312012948000_4.1.e000638.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"2025090312012948000_4.1.e000638.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210724"},{"key":"2025090312012948000_4.1.e000638.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205056"},{"key":"2025090312012948000_4.1.e000638.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207963"},{"key":"2025090312012948000_4.1.e000638.22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151376"},{"key":"2025090312012948000_4.1.e000638.23","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090312012948000_4.1.e000638.24","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090312012948000_4.1.e000638.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2025090312012948000_4.1.e000638.26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20162"},{"key":"2025090312012948000_4.1.e000638.27","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22529"},{"key":"2025090312012948000_4.1.e000638.28","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150805"},{"key":"2025090312012948000_4.1.e000638.29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/00325481.2016.1220809","article-title":"Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study","volume":"128","author":"Perrotta","year":"2016","journal-title":"Postgrad Med"},{"key":"2025090312012948000_4.1.e000638.30","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120970"},{"key":"2025090312012948000_4.1.e000638.31","doi-asserted-by":"crossref","unstructured":"Mease P , Deodhar A , Fleischmann R , et al . Effect of certolizumab pegol over 96\u2005weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open 2015;1.doi:10.1136\/rmdopen-2015-000119","DOI":"10.1136\/rmdopen-2015-000119"},{"key":"2025090312012948000_4.1.e000638.32","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22576"},{"key":"2025090312012948000_4.1.e000638.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201972"},{"key":"2025090312012948000_4.1.e000638.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202812"},{"key":"2025090312012948000_4.1.e000638.35","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20155"},{"key":"2025090312012948000_4.1.e000638.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203018"},{"key":"2025090312012948000_4.1.e000638.37","doi-asserted-by":"publisher","DOI":"10.1002\/art.37876"},{"key":"2025090312012948000_4.1.e000638.38","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1007\/s10067-016-3425-4","article-title":"Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature","volume":"35","author":"Reddy","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2025090312012948000_4.1.e000638.39","doi-asserted-by":"crossref","unstructured":"Maneiro JR , Souto A , Salgado E , et al . Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open 2015;1.doi:10.1136\/rmdopen-2014-000017","DOI":"10.1136\/rmdopen-2014-000017"},{"key":"2025090312012948000_4.1.e000638.40","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/acr.22257","article-title":"Analysis of trial data for infliximab and golimumab: baseline C-reactive protein level and prediction of therapeutic response in patients with psoriatic arthritis","volume":"66","author":"Au","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2025090312012948000_4.1.e000638.41","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/jdv.13024","article-title":"TNF-alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients","volume":"29","author":"De Simone","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090312012948000_4.1.e000638.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205417"},{"key":"2025090312012948000_4.1.e000638.43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11926-015-0518-z","article-title":"Pharmacogenetics of treatment response in psoriatic arthritis","volume":"17","author":"Jani","year":"2015","journal-title":"Curr Rheumatol Rep"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2017-000638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:01:41Z","timestamp":1756926101000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2017-000638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,4,25]]},"published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1136\/rmdopen-2017-000638"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2017-000638","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}